Ge-68/Ga-68 Generator provides an excellent source for the positron-emitting - radionuclide Ga-68. Ga-68 obtained from this generator can be used for PET systems calibration, for making phantoms and for the development of labeling technique.
The parent radionuclide Ge-68 has a half-life of 270.95 days which ensures the cost-effective availability of 68Ga within the PET facility, where it can be used as the source of Ga-68 for at least 1 year.

Gallium-68 (with a half-life of only 67.71 minutes) can be easily eluted from the generator any time at the site of application and can be used for different purposes.

MIBI evaluation of the myocardium perfusion at its different pathological states and for the scintigraphy of the malignant tumors of the lung and breast
RBC diagnostic agent for Cardiac Function and Blood Pool Scans
DMSA scintigraphy of the renal cortex
MDP bone scintigraphy
Sulfur Colloid diagnostic agent for GI system, liver/spleen scintigraphy

Strontium-89 Chloride Injection is mainly used for treatment of pain caused by metastasis of advanced malignant cancer such as prostate cancer, breast cancer, lung cancer and nasopharyngeal carcinoma, and inhibits the new metastasis of malignant cancers.
Sr-89 is an important treatment for cancer bone metastasis pain. Metastatic bone lesions are zones of high bone mineral turnover, and there is a constant need of calcium supply for the development of the malignancy.

Strontium chloride 89 is a divalent ion, similar to calcium, therefore it is taken up by sites of active osteogenesis. This relieves bone metastatic-driven pain without generating important side effects and it also presents a very little radioprotection concern (Giammarile F, Mognetti T, Resche I: Bone pain palliation with strontium-89 in cancer patients with bone metastases.

Radioiodine has the distinction of being the first theranostic agent in our armamentarium, I-131 being gamma and beta emitter can be used in diagnostic and therapeutic thyroid applications, industrial tracers, and various research applications such as antibody labelling. Iodine-131 is also used to label antibodies for therapeutic applications in the treatment of cancers.
Iodine is essential for proper function of the thyroid gland, which uses it to make the thyroid hormones. The thyroid is equipped with an active system called " Na + /I-thyroid symporter pump " for moving iodine into its cells.

Because the ability of thyroid cells to take up radioiodine I-131 or RAI exactly like iodine, it has been used by medical professionals to diagnose and treat various thyroid diseases.

I-125 Brachytherapy Seeds can be used for a variety of tumors, including prostatic cancer, pulmonary cancer, hepatocellular carcinoma and pancreatic cancer and pancreatic metastasis. It is also used to treat remaining tumor and recurrence that has been treated by radiation.
Iodine-125 low dose rate brachytherapy (BT) is an effective modality to administer a high dose to the prostate while minimizing toxicities for the adjacent organs at risk. For selected patients with low and favorable intermediate-risk prostate cancer, BT might be equally effective in controlling the disease as radical prostatectomy.

Tc-99m generators are used for imaging and studying organs such as the brain, heart muscle, thyroid, lungs, liver, gallbladder and kidneys, as well as the skeleton and blood and for the investigation of tumors.
Sodium Pertechnetate (Tc99m) solution is used only for diagnostic purposes.

The elution solution derived from generator (Sodium Pertechnetate- Tc99m) can be used for labelling of various carrying ingredients(kits) as well as it can directly be injected to the patient. When Sterile Sodium Pertechnetate- Tc99m solution was applied intravenously, it can be used for the following indications for diagnoses purposes.

Ac-225 is a high energy alpha-emitting radioisotope with therapeutic applications as a Targeted Alpha Therapy (TAT) for certain cancers and HIV.

Studies shows remarkable therapeutic efficacy with using Ac-225 in treating prostate cancer.
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue.

177Lu has virtually pervaded all areas of in vivo radionuclide therapy and may be poised to become a key therapeutic radionuclide of choice for targeted radionuclide therapy (TRT).
The growing interest in the use of 177Lu in targeted molecular therapies has primarily developed from recent unprecedented advances in molecular and cell biology, which include the use of peptides targeted to cell surface receptors, which are overexpressed on the surface of tumor cells.